NCT00517153 - Miglustat in Niemann-Pick Type C Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2002

Primary Completion Date

September 30, 2006

Study Completion Date

January 31, 2008

Conditions

Niemann-Pick Type C Disease

Interventions

DRUG

miglustat

Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA